Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Neurobiology of Aging
|
April 18, 2002
Interactions between aging and cortical cholinergic deafferentation on attention
Joshua A Burk, Christopher D Herzog, M Christine Porter, et al.
Neurobiology of Aging
|
August 21, 2003
Microdialysis without acetylcholinesterase inhibition reveals an age-related attenuation in stimulated cortical acetylcholine release
Christopher D Herzog, Kelly A Nowak, Martin Sarter, et al.
Drug Delivery and Translational Research
|
March 20, 2015
Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases
Christopher D Herzog, Kathie M Bishop, Lamar Brown, et al.
Neurobiology of Aging
|
August 29, 2012
Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease
Raymond T Bartus, Tiffany L Baumann, Lamar Brown, et al.
Parkinsonism & Related Disorders
|
November 19, 2008
Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point
Raymond T Bartus, Christopher D Herzog, Kathie Bishop, et al.
Neurobiology of Disease
|
March 6, 2007
Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease
Shilpa Ramaswamy, Jodi L McBride, Christopher D Herzog, et al.
Annals of Neurology
|
December 29, 2006
Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys
Jeffrey H Kordower, Christopher D Herzog, Biplob Dass, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
December 14, 2006
Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease
Mehdi Gasmi, Christopher D Herzog, Eugene P Brandon, et al.
Neurobiology of Disease
|
June 28, 2011
Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease
Raymond T Bartus, Lamar Brown, Alistair Wilson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
April 20, 2007
Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys
Christopher D Herzog, Biplob Dass, James E Holden, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Neurobiology of Aging
|
April 18, 2002
Interactions between aging and cortical cholinergic deafferentation on attention
Joshua A Burk, Christopher D Herzog, M Christine Porter, et al.
Neurobiology of Aging
|
August 21, 2003
Microdialysis without acetylcholinesterase inhibition reveals an age-related attenuation in stimulated cortical acetylcholine release
Christopher D Herzog, Kelly A Nowak, Martin Sarter, et al.
Drug Delivery and Translational Research
|
March 20, 2015
Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases
Christopher D Herzog, Kathie M Bishop, Lamar Brown, et al.
Neurobiology of Aging
|
August 29, 2012
Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease
Raymond T Bartus, Tiffany L Baumann, Lamar Brown, et al.
Parkinsonism & Related Disorders
|
November 19, 2008
Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point
Raymond T Bartus, Christopher D Herzog, Kathie Bishop, et al.
Neurobiology of Disease
|
March 6, 2007
Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease
Shilpa Ramaswamy, Jodi L McBride, Christopher D Herzog, et al.
Annals of Neurology
|
December 29, 2006
Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys
Jeffrey H Kordower, Christopher D Herzog, Biplob Dass, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
December 14, 2006
Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease
Mehdi Gasmi, Christopher D Herzog, Eugene P Brandon, et al.
Neurobiology of Disease
|
June 28, 2011
Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease
Raymond T Bartus, Lamar Brown, Alistair Wilson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
April 20, 2007
Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys
Christopher D Herzog, Biplob Dass, James E Holden, et al.
Page
of 2